Mayne Pharma Group (MAYNF)
OTHER OTC:MAYNF
MAYNF Stock Chart & Stats
$3.82
-$0.09(-2.96%)
At close: 4:00 PM EST
$3.82
-$0.09(-2.96%)
Day’s Range― - ―
52-Week Range$1.63 - $4.59
Previous CloseN/A
Volume375.00
Average Volume (3M)2.61K
Market Cap
$125.91M
Enterprise Value$167.39M
Total Cash (Recent Filing)$67.35M
Total Debt (Recent Filing)$44.62M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding81,245,830
10 Day Avg. Volume15
30 Day Avg. Volume2,610
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market Cap1.33
Enterprise Value/Revenue0.41
Enterprise Value/Gross Profit0.75
Enterprise Value/Ebitda7.16
Forecast
1Y Price Target
$4.32Price Target Upside13.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Group Gross MarginA ~3.9ppt gross margin expansion signals a durable shift to higher-quality revenue mix and better margin control. Sustained higher gross margins provide structural support for profitability, help absorb SG&A and legal costs, and improve cash generation potential over the medium term.
Dermatology Margin TurnaroundDermatology’s 12ppt margin lift and 35% contribution growth, driven by a branded mix, reflects a structural move away from low‑margin commoditized sales. Branded dermatology typically offers stickier demand and pricing power, supporting sustainable higher margins and earnings stability.
Positive Operating Cash Flow & Cash BalanceReported adjusted OCF and a $67.3m liquidity buffer give the company durable financial optionality. That cash can fund promotional investment, Salisbury capacity upgrades, litigation or targeted M&A without immediate external financing, supporting execution of strategic repositioning.
Bears Say
Negative Profitability / ROEDeep negative net margins and a substantially negative ROE indicate the company is not generating returns on shareholder capital. Until core profitability sustainably reverses, equity value creation is constrained and reinvestment or shareholder distributions remain limited.
Weak Cash‑flow ConversionSevere FCF compression and very low operating‑cash‑to‑income conversion show earnings are not reliably turning into cash. This structural weakness reduces financial flexibility, heightens refinancing and funding risk, and limits ability to sustain investment or absorb shocks.
One‑offs, Litigation And Return RiskLarge noncash earn‑out adjustments and elevated litigation/transaction charges create recurring volatility and potential cash outflows. Combined with product return dynamics (e.g., ANNOVERA), these structural risks impair predictability of earnings and complicate capital allocation decisions.
Mayne Pharma Group News
MAYNF FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest stock price was $1.63 and its highest was $4.59 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is $125.91M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 147 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -$0.107 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.107.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Undervalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of $0.378 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -$0.107 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.424%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in MAYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.32 (13.12% Upside)
$4.32 (13.12% Upside)
Blogger Sentiment
Bullish
MAYNF Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth AU$401.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MAYNF Company Deck
MAYNF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all MAYNF earnings summariesMAYNF Stock 12 Month Forecast
Average Price Target
$4.32
▲(13.12% Upside)
Technical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
0.34% Insiders
3.24% Mutual Funds
<0.01% Other Institutional Investors
94.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---